--- title: "ProKidney (PROK) news: offering" url: "https://aibio.space/companies/prokidney/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PROK offering news: ProKidney sets up at-the-market program for up to $200,000,000 of stock with Jefferies. ProKidney Corp. (NASDAQ: PROK), United States." --- PROK ProKidney Corp. NASDAQ · United States # ProKidney (PROK) news PROK offering news Financings · 2026-10-29 ## [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) ProKidney can sell up to $200,000,000 of Class A stock through Jefferies LLC at a commission of up to 3.0%, under a $650,000,000 shelf that the filings say must take effect before any sale. The stock last sold at $1.52 on October 28, 2026. ## Latest ProKidney news 1. 2025-07-14 Financings [ProKidney sets up at-the-market program for up to $200,000,000 of stock with Jefferies](https://aibio.space/news/prokidney-sets-up-market-program-up-200-000-000-stock-jefferies/) Jefferies earns up to 3.0% of gross proceeds on the new $200,000,000 program. The stock last sold at $4.54 on July 11, 2025, and the second dosing group in the Phase 2 REGEN-007 trial missed statistical significance. 2. 2025-03-31 Mergers [ProKidney files to move incorporation from the Cayman Islands to Delaware](https://aibio.space/news/prokidney-files-move-incorporation-cayman-islands-delaware/) ProKidney's plan would move a Cayman Islands company to Delaware and register up to 292,707,888 shares. Its Class B shares have no public market, and the new charter would bar shareholder action by written consent. ## ProKidney at a glance - **Ticker**: PROK - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $74.9 million ### Related companies - [Nevis Brands](https://aibio.space/companies/nevis-brands/) CSE: NEVI - [Contineum Therapeutics](https://aibio.space/companies/contineum-therapeutics/) NASDAQ: CTNM - [CLARITAS PHARMACEUTICALS INC.](https://aibio.space/companies/claritas-pharmaceuticals/) OTC: CLAZF - [Greenwich LifeSciences](https://aibio.space/companies/greenwich-lifesciences/) NASDAQ: GLSI - [Aptevo Therapeutics](https://aibio.space/companies/aptevo-therapeutics/) NASDAQ: APVO - [Seres Therapeutics](https://aibio.space/companies/seres-therapeutics/) NASDAQ: MCRB - [Gain Therapeutics](https://aibio.space/companies/gain-therapeutics/) NASDAQ: GANX - [GlobeStar Therapeutics](https://aibio.space/companies/globestar-therapeutics/) OTC: GSTC ### Also on NASDAQ - [INTUITIVE SURGICAL INC](https://aibio.space/companies/intuitive-surgical/) ISRG - [NeuroSense Therapeutics](https://aibio.space/companies/neurosense-therapeutics/) NRSN - [TG Therapeutics](https://aibio.space/companies/tg-therapeutics/) TGTX - [Biogen](https://aibio.space/companies/biogen/) BIIB - [ADMA Biologics](https://aibio.space/companies/adma-biologics/) ADMA - [INTELLIGENT BIO SOLUTIONS INC.](https://aibio.space/companies/intelligent-bio-solutions/) INBS ## ProKidney annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$114.1 million](https://www.sec.gov/Archives/edgar/data/1850270/000119312526113881/) | [$127.7 million](https://www.sec.gov/Archives/edgar/data/1850270/000119312526113881/) | | Net income (loss) | [-$69.0 million](https://www.sec.gov/Archives/edgar/data/1850270/000119312526113881/) | [-$61.2 million](https://www.sec.gov/Archives/edgar/data/1850270/000119312526113881/) | | Cash from operations | [-$120.1 million](https://www.sec.gov/Archives/edgar/data/1850270/000119312526113881/) | [-$126.4 million](https://www.sec.gov/Archives/edgar/data/1850270/000119312526113881/) | | Cash and equivalents | [$108.5 million](https://www.sec.gov/Archives/edgar/data/1850270/000119312526342373/) | [$99.1 million](https://www.sec.gov/Archives/edgar/data/1850270/000119312526113881/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $74.9 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about ProKidney Has ProKidney raised money recently? Our latest story on this, dated Jul 14, 2025: "ProKidney sets up at-the-market program for up to $200,000,000 of stock with Jefferies". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/prokidney-sets-up-market-program-up-200-000-000-stock-jefferies/). What is the ticker symbol of ProKidney? ProKidney Corp. trades under the ticker PROK on NASDAQ. Where is ProKidney listed? ProKidney Corp. is listed on NASDAQ. Our directory also records these other listings: BIVA:PROK; BMV:PROK. What is the SEC CIK of ProKidney? The SEC Central Index Key (CIK) for ProKidney Corp. is 1850270. Its filings are on SEC EDGAR. Which country or territory is ProKidney listed under? Our directory records ProKidney Corp. under United States. What does ProKidney do? Our directory classifies ProKidney Corp. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of ProKidney? The ISIN recorded for ProKidney Corp. is US74291D1046. Does aibio.space cover ProKidney? aibio.space lists ProKidney Corp. among 2,820 public biotech companies and publishes its news here as stories appear. Where is ProKidney incorporated? SEC records list its state or country of incorporation as E9. Is ProKidney profitable? ProKidney Corp. reported a net loss of $69.0 million for the fiscal year ended Dec 31, 2025, and used $120.1 million of cash in operations, per its annual report to the SEC. How much does ProKidney spend on research and development? $114.1 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does ProKidney have? $74.9 million in cash at Jun 30, 2026, per its 10-Q. What is the latest ProKidney (PROK) stock news? Our latest story on ProKidney, dated Oct 29, 2026: "ProKidney files $650 million shelf with $200 million Jefferies sales program". ProKidney can sell up to $200,000,000 of Class A stock through Jefferies LLC at a commission of up to 3.0%, under a $650,000,000 shelf that the filings say must take effect before any sale. The stock last sold at $1.52 on October 28, 2026. [Source](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/). How long will ProKidney's cash last? From our story of Oct 29, 2026: Cash, losses and the going concern language [Source](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/). Is ProKidney being acquired or merging? Our latest merger story, dated Mar 31, 2025: "ProKidney files to move incorporation from the Cayman Islands to Delaware". ProKidney's plan would move a Cayman Islands company to Delaware and register up to 292,707,888 shares. Its Class B shares have no public market, and the new charter would bar shareholder action by written consent. [Source](https://aibio.space/news/prokidney-files-move-incorporation-cayman-islands-delaware/). ## Investor discussion: ProKidney Members talk about ProKidney (PROK). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at ProKidney, newest first. Each line links the filing it comes from. 1. 2026-10-29 Financings Reported a financing. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1850270/000119312526437924/d81716ds3.htm) 2. 2026-08-10 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1850270/000119312526342373/prok-20260630.htm) 3. 2025-07-14 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1850270/000114036125025800/ny20051951x1_424b5.htm) 4. 2025-03-31 Mergers Filed documents for a merger or acquisition. SEC Form S-4. [Source](https://www.sec.gov/Archives/edgar/data/1850270/000114036125011383/ny20045101x1_s4.htm) 5. 2025-01-21 Financings Reported a financing. SEC Form 8-K (Items 1.01). [Source](https://www.sec.gov/Archives/edgar/data/1850270/000095017025007217/prok-20250117.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PROK on TradingView](https://www.tradingview.com/symbols/NASDAQ-PROK/). ## SEC filings and registration - **SEC name**: Prokidney Corp. - **CIK**: 1850270 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: PROK (Nasdaq) - **State or country of incorporation**: E9 - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 2000 FRONTIS PLAZA BLVD., WINSTON-SALEM, NC, 27103 - **Phone**: 336-999-7028 - **Former names**: Social Capital Suvretta Holdings Corp. III ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1850270/000119312526342397/prok-20260810.htm) filed 2026-08-10 - [10-Q](https://www.sec.gov/Archives/edgar/data/1850270/000119312526342373/prok-20260630.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1850270/000119312526248210/prok-20260528.htm) filed 2026-05-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1850270/000119312526225848/prok-20260515.htm) filed 2026-05-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/1850270/000119312526225841/prok-20260331.htm) filed 2026-05-15 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1850270/000114036126015362/ny20066059x1_def14a.htm) filed 2026-04-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1850270/000119312526113893/prok-20260318.htm) filed 2026-03-18 - [10-K](https://www.sec.gov/Archives/edgar/data/1850270/000119312526113881/prok-20251231.htm) filed 2026-03-18 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001850270), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details ProKidney Corp. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PROK, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: ProKidney Corp. - **Ticker**: PROK - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US74291D1046 - **Other listed symbols**: BIVA:PROK; BMV:PROK - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PROK/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/prokidney/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ProKidney (PROK) news: offering", 2026-10-31, https://aibio.space/companies/prokidney/